PE20060570A1 - Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10 - Google Patents

Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10

Info

Publication number
PE20060570A1
PE20060570A1 PE2005000840A PE2005000840A PE20060570A1 PE 20060570 A1 PE20060570 A1 PE 20060570A1 PE 2005000840 A PE2005000840 A PE 2005000840A PE 2005000840 A PE2005000840 A PE 2005000840A PE 20060570 A1 PE20060570 A1 PE 20060570A1
Authority
PE
Peru
Prior art keywords
phenyl
quinazoline
inhibitors
pde
isoquinoline
Prior art date
Application number
PE2005000840A
Other languages
English (en)
Inventor
Thomas Allen Chappie
John Michael Humphrey
Spiros Liras
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34972555&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060570(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20060570A1 publication Critical patent/PE20060570A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A DERIVADOS DE QUINAZOLINA E ISOQUINOLINA SUSTITUIDOS CON PIPERIDILO DE FORMULA (I), EN DONDE X, Y Y Z SON INDEPENDIENTEMENTE N O CH Y SIEMPRE QUE Z SEA N, Y ES CH; Y CUANDO Y ES N, X ES N Y Z ES CH; R1, R2 Y R5 SON INDEPENDIENTEMENTE H, HALOGENO, CN, COOR3, ALCOXI(C1-C9), ENTRE OTROS; R ES H, ALCOXI(C1-C5), -COOR3, CONR3R4, -COR4, NR3R4, NHCOR3, -OH, CN, ALQUILO, ENTRE OTROS; B ES H, FENILO, NAFTILO O HETEROARILO DE 5 A 6 MIEMBROS, OPCIONSLMENTE SUSTITUIDOS CON ALCOXI(C1-C5), ALQUILO(C1-C5), TRIFLUOROALQUILO O TRIFLUOROALCOXI(C2-C5), ENTRE OTROS, SON PREFERIDOS: N-[1-(6,7-DIMETOXI-QUINAZOLIN-4-IL)-3-FENIL-PIPERIDIN-4-IL]-BENZAMIDA, N-[1-(6,7-DIMETOXI-QUINAZOLIN-4-IL)-3-FENIL-PIPERIDIN-4-IL]-2,2-DIMETIL-PROPIONAMIDA, 1-(6-ETOXI-7-METOXI-QUINAZOLIN-4-IL)-5-FENIL-PIPERIDIN-3-OL, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE ELABORACION, A PRODUCTOS INTERMEDIOS Y A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON INHIBIDORES DE LA FOSFODIESTERASA (PDE) SELECTIVAMENTE DE PDE-10, POR LO QUE SON UTILES EN EL TRATAMIENTO DE TRANSTORNOS NEURODEGENERATIVOS Y PSIQUIATRICOS
PE2005000840A 2004-07-23 2005-07-20 Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10 PE20060570A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59094304P 2004-07-23 2004-07-23

Publications (1)

Publication Number Publication Date
PE20060570A1 true PE20060570A1 (es) 2006-07-14

Family

ID=34972555

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000840A PE20060570A1 (es) 2004-07-23 2005-07-20 Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10

Country Status (25)

Country Link
US (1) US20060019975A1 (es)
EP (1) EP1773805A1 (es)
JP (1) JP2008507500A (es)
CN (1) CN1989124A (es)
AP (1) AP2007003891A0 (es)
AR (1) AR050433A1 (es)
AU (1) AU2005266080A1 (es)
BR (1) BRPI0513475A (es)
CA (1) CA2574685A1 (es)
CR (1) CR8861A (es)
EA (1) EA200700097A1 (es)
EC (1) ECSP077193A (es)
GT (1) GT200500198A (es)
IL (1) IL180205A0 (es)
MA (1) MA28746B1 (es)
MX (1) MX2007000878A (es)
NL (1) NL1029596C2 (es)
NO (1) NO20065948L (es)
PE (1) PE20060570A1 (es)
SV (1) SV2006002175A (es)
TN (1) TNSN07021A1 (es)
TW (1) TW200616641A (es)
UY (1) UY29028A1 (es)
WO (1) WO2006011040A1 (es)
ZA (1) ZA200700223B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1796669B1 (en) * 2004-10-01 2010-09-22 Merck Sharp & Dohme Corp. Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2006094034A1 (en) * 2005-03-01 2006-09-08 Wyeth Cinnoline compounds and their use as liver x receptor modilators
BRPI0707223A2 (pt) * 2006-01-27 2011-04-26 Pfizer Prod Inc compostos de derivados de aminoftalazina
EP1991530A1 (en) * 2006-02-21 2008-11-19 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
CA2643983A1 (en) * 2006-02-21 2007-08-30 Amgen, Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
EP1991531A1 (en) * 2006-02-28 2008-11-19 Amgen Inc. Cinnoline and quinoxaline derivates as phosphodiesterase 10 inhibitors
US20090099175A1 (en) * 2006-03-01 2009-04-16 Arrington Mark P Phosphodiesterase 10 inhibitors
US20070265258A1 (en) * 2006-03-06 2007-11-15 Ruiping Liu Quinazoline derivatives as phosphodiesterase 10 inhibitors
JP2009529060A (ja) * 2006-03-08 2009-08-13 アムゲン インコーポレイティッド ホスホジエステラーゼ１０阻害剤としてのキノリン及びイソキノリン誘導体
WO2007119361A1 (ja) * 2006-03-17 2007-10-25 Mitsubishi Gas Chemical Company, Inc. キナゾリン－４－オン誘導体の製造方法
US8492394B2 (en) * 2006-07-10 2013-07-23 H. Lundbeck A/S (3-aryl-piperazin-1-yl), (2-aryl-morpholin-4-yl) and (2-aryl-thiomorpholin-4-yl) derivatives of 6,7-dialkoxy-quinazoline, 6,7-dialkoxyphtalazine and 6,7-dialkoxyisoquinoline as PDE10A enzyme inhibitors
EP1903038A1 (de) * 2006-09-07 2008-03-26 Bayer Schering Pharma Aktiengesellschaft N-(1-Hetaryl-piperidin-4-yl)-(het)arylamide als EP2-Rezeptor Modulatoren
EP1903037A1 (de) * 2006-09-07 2008-03-26 Bayer Schering Pharma Aktiengesellschaft 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioharnstoffe als Modulatoren des EP2-Rezeptors
WO2009025839A2 (en) * 2007-08-22 2009-02-26 Amgen Inc. Phosphodiesterase 10 inhibitors
US7858620B2 (en) * 2007-09-19 2010-12-28 H. Lundbeck A/S Cyanoisoquinoline
TW200918519A (en) * 2007-09-19 2009-05-01 Lundbeck & Co As H Cyanoisoquinoline
UA102693C2 (ru) 2008-06-20 2013-08-12 Х. Луннбек А/С Производные фенилимидазола как ингибиторы фермента pde10a
ES2397934T3 (es) 2008-12-17 2013-03-12 Amgen Inc. Compuestos de aminopiridina y carboxipiridina como inhibidores de fosfodiesterasa 10
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
TWI487705B (zh) 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基***衍生物
TW201200516A (en) 2009-12-17 2012-01-01 Lundbeck & Co As H Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
CA2800578A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Nitrogen-heterocyclic compounds as phosphodiesterase 10 inhibitors
AU2011253057B2 (en) 2010-05-13 2014-11-20 Amgen Inc. Nitrogen heterocyclic compounds useful as PDE10 inhibitors
WO2011143366A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Heteroaryloxycarbocyclyl compounds as pde10 inhibitors
MX2012013127A (es) 2010-05-13 2012-11-30 Amgen Inc Compuestos heteroariloxiheterociclilo como inhibidores pde10.
TW201215607A (en) 2010-07-02 2012-04-16 Lundbeck & Co As H Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor
TW201206935A (en) 2010-07-16 2012-02-16 Lundbeck & Co As H Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor
DE102010042833B4 (de) 2010-10-22 2018-11-08 Helmholtz-Zentrum Dresden - Rossendorf E.V. Neue Halogenalkoxychinazoline, deren Herstellung und Verwendung
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
BR112013021180A2 (pt) 2011-02-18 2019-09-24 Allergan Inc derivados de 6,7-dialcóxi-3-isoquinolinol substituído como inibidores de fosfodiesterase 10 (pde10a)
WO2013045607A1 (en) 2011-09-30 2013-04-04 H. Lundbeck A/S Quinazoline linked heteroaromatic tricycle derivatives as pde10a enzyme inhibitors
WO2013050527A1 (en) 2011-10-05 2013-04-11 H. Lundbeck A/S Quinazoline derivatives as pde10a enzyme inhibitors
AR089361A1 (es) 2011-12-21 2014-08-20 Lundbeck & Co As H Derivados de quinolina como inhibidores de la enzima pde10a
WO2013127817A1 (en) 2012-02-27 2013-09-06 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
TW201348231A (zh) 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
EP2855453B1 (en) 2012-06-04 2016-12-07 Actelion Pharmaceuticals Ltd. Benzimidazole-proline derivatives
CN104703980B (zh) 2012-10-10 2017-09-22 埃科特莱茵药品有限公司 属于[邻双(杂)芳基]‑[2‑(间双(杂)芳基)吡咯烷‑1‑基]甲酮衍生物的食欲素受体拮抗剂
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
KR20150130413A (ko) 2013-03-12 2015-11-23 액테리온 파마슈티칼 리미티드 오렉신 수용체 길항제로서의 아제티딘 아미드 유도체
LT3077391T (lt) 2013-12-04 2018-10-25 Idorsia Pharmaceuticals Ltd Benzimidazolo prolino darinių panaudojimas
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
US10005764B2 (en) * 2014-04-04 2018-06-26 H. Lundbeck A/S Halogenated quinazolin-THF-amines as PDE1 inhibitors
CN106632089B (zh) * 2016-11-04 2019-06-18 中山大学 一类喹唑啉类化合物及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3517005A (en) * 1967-10-26 1970-06-23 Pfizer & Co C Certain 2- and 4-substituted quinazolines
GB1460389A (en) * 1974-07-25 1977-01-06 Pfizer Ltd 4-substituted quinazoline cardiac stimulants
IN148482B (es) * 1977-06-03 1981-03-07 Pfizer
JPS60120872A (ja) * 1983-12-01 1985-06-28 Kyowa Hakko Kogyo Co Ltd 新規なヘテロ環状化合物及び強心剤
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
EP0638567A4 (en) * 1993-02-18 1995-05-10 Kyowa Hakko Kogyo Kk ADENOSINE INHIBITORS.
CA2148260A1 (en) * 1993-09-10 1995-03-16 Yasutaka Takase Quinazoline cpompounds
JP3919272B2 (ja) * 1996-12-18 2007-05-23 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナゾリン系化合物
US20030032579A1 (en) * 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
WO2002088107A1 (en) * 2001-04-26 2002-11-07 Eisai Co., Ltd. Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof
JP4782564B2 (ja) * 2002-07-10 2011-09-28 メルク セローノ ソシエテ アノニム アゾリジノン−ビニル縮合−ベンゼン誘導体

Also Published As

Publication number Publication date
GT200500198A (es) 2006-03-02
AR050433A1 (es) 2006-10-25
US20060019975A1 (en) 2006-01-26
NL1029596A1 (nl) 2006-01-24
UY29028A1 (es) 2006-02-24
EP1773805A1 (en) 2007-04-18
CR8861A (es) 2007-03-02
MA28746B1 (fr) 2007-07-02
SV2006002175A (es) 2006-02-15
IL180205A0 (en) 2007-07-04
TNSN07021A1 (fr) 2008-06-02
NL1029596C2 (nl) 2006-09-06
AP2007003891A0 (en) 2007-02-28
MX2007000878A (es) 2007-03-12
ECSP077193A (es) 2007-02-28
CN1989124A (zh) 2007-06-27
TW200616641A (en) 2006-06-01
JP2008507500A (ja) 2008-03-13
AU2005266080A1 (en) 2006-02-02
NO20065948L (no) 2007-01-23
EA200700097A1 (ru) 2007-06-29
WO2006011040A1 (en) 2006-02-02
BRPI0513475A (pt) 2008-05-06
CA2574685A1 (en) 2006-02-02
ZA200700223B (en) 2008-08-27

Similar Documents

Publication Publication Date Title
PE20060570A1 (es) Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10
NO20051051L (no) Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme i terapeutiske midler
NI201000150A (es) Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilización.
CO5700824A2 (es) Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
ECSP055640A (es) Composiciones de pirazol útiles como inhibidores de gsk-3
AR046085A1 (es) Agonistas etilamino amino sustituidos del receptor beta 2 adrenergico
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR056691A1 (es) Derivados pirrolopirimidina como inhibidores de syk
AR052866A1 (es) Fenil-metanonas monociclicas sustituidas
EA200970461A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
CO5700757A2 (es) Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
NO20063821L (no) Kinolinderivater for anvendelse som mykobakterielle inhibitorer
AR063906A1 (es) Compuestos quimicos derivados del indazol, una composicion farmaceutica y procesos de prpeparacion de los compuestos
ATE431345T1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
AR066972A1 (es) Derivados azapeptidicos
PE20191784A1 (es) Compuestos inhibidores de vmat2, composiciones y metodos relativos a los mismos
EA201000101A1 (ru) Производные пиримидина 934
AR075975A1 (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintetasa quinasa 3
NO20062417L (no) N-tiazol-2-yl-benzamidderivater
AR054725A1 (es) Pirazolopiridinas y sales de las mismas, una composicion farmaceutica que comprende dichos compuestos, un metodo para prepararlos y su uso
CL2008002654A1 (es) Compuestos derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, bloqueadores de los canales hcn; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cardiopatias isquemicas, insuficiencias cardiacas tanto sistolicas como diastolicas, entre otras.
AR053340A1 (es) Derivados de trifluormetilbenzamida y sus usos terapeuticos

Legal Events

Date Code Title Description
FD Application declared void or lapsed